Partnerships

Vedanta has been awarded BARDA funding to advance VE303 through clinical and regulatory development for CDI. The contract provides for reimbursement of up to $114.2 million, subject to additional prespecified milestones being achieved and the availability of funding.

Vedanta has been awarded two research grants from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the development of VE303, the Company’s product candidate for the treatment of high-risk C. difficile infection (CDI), and VE707, Vedanta’s preclinical discovery program for the prevention of infection and recurrence of several MDROs, including carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta lactamase producers (ESBL), and vancomycin-resistant Enterococci (VRE).